Sánchez-Valledor LF, Habermann TM, Murrieta-Alvarez I, Córdova-Ramírez AC, Rivera-Álvarez M, León-Peña A, Cantero-Fortiz Y, Olivares-Gazca JC, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. Long-term results of the treatment of Hodgkin’s lymphoma in a resource-constrained setting: Real-world data from a single center. World J Clin Oncol 2021; 12(9): 800-807 [PMID: 34631443 DOI: 10.5306/wjco.v12.i9.800]
Corresponding Author of This Article
Guillermo José Ruiz-Argüelles, FRCP (Glasg), MACP, DSc (hc), FRCP, MD, Professor, Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla 72530, Mexico. gruiz1@hsctmexico.com
Research Domain of This Article
Hematology
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Sep 24, 2021; 12(9): 800-807 Published online Sep 24, 2021. doi: 10.5306/wjco.v12.i9.800
Long-term results of the treatment of Hodgkin’s lymphoma in a resource-constrained setting: Real-world data from a single center
Luisa Fernanda Sánchez-Valledor, Thomas M Habermann, Iván Murrieta-Alvarez, Alejandra Carmina Córdova-Ramírez, Montserrat Rivera-Álvarez, Andrés León-Peña, Yahveth Cantero-Fortiz, Juan Carlos Olivares-Gazca, Guillermo José Ruiz-Delgado, Guillermo José Ruiz-Argüelles
Luisa Fernanda Sánchez-Valledor, Escuela de Medicina, Universidad de las Américas Puebla, Cholula 72810, Puebla, Mexico
Thomas M Habermann, Department of Medicine, Division of Hematology, Mayo Clinical and Mayo Foundation, Rochester, MN 55905, United States
Iván Murrieta-Alvarez, Andrés León-Peña, Yahveth Cantero-Fortiz, Juan Carlos Olivares-Gazca, Guillermo José Ruiz-Delgado, Guillermo José Ruiz-Argüelles, Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla 72530, Mexico
Alejandra Carmina Córdova-Ramírez, Montserrat Rivera-Álvarez, Escuela de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla 72410, Mexico
Author contributions: Ruiz-Agüelles GJ, Habermann TM and Ruiz-Delgado GJ conceptualized and designed the study; Ruiz-Argüelles GJ, Ruiz-Delgado, Murrieta-Álvarez I wrote the manuscript; Murrieta-Álvarez I, Cantero-Fortiz Y, León-Peña A and Rivera-Álvarez M conducted the analyses; Rivera-Álvarez M, Córdova-Ramírez AC, and Olivares-Gazca JC collected data; All authors have read and approved the final manuscript.
Institutional review board statement: This study was approved by the Centro de Hematología y Medicina Interna, Clínica Ruiz Institutional Review Board.
Informed consent statement: Informed consent was waived by the Institutional Review Board.
Conflict-of-interest statement: The authors declare that they have no conflicting interests.
Data sharing statement: Data are available upon request.
STROBE statement: The authors have read the STROBE Statement, and the manuscript was prepared and revised according to the STROBE Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Guillermo José Ruiz-Argüelles, FRCP (Glasg), MACP, DSc (hc), FRCP, MD, Professor, Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla 72530, Mexico. gruiz1@hsctmexico.com
Received: January 4, 2021 Peer-review started: January 4, 2021 First decision: May 4, 2021 Revised: May 17, 2021 Accepted: August 9, 2021 Article in press: August 9, 2021 Published online: September 24, 2021 Processing time: 255 Days and 14.3 Hours
ARTICLE HIGHLIGHTS
Research background
Hodgkin´s lymphoma (HL) can be treated with different alternatives, the performance of newer and older chemotherapy schemes are unknown in some circumstances.
Research motivation
The motivation was to describe the performance of treatment of HL in a middle-income country.
Research objectives
The objective was to determine performance of classic therapies for HL.
Research methods
This was a comparative study of therapies for HL in a single center over a long-term period.
Research results
HL may be less aggressive in the Mexican population. In addition, the classical ABVD regimen achieved long-term survival in a significant proportion of patients.
Research conclusions
Combined chemotherapy has acceptable efficacy in patients with HL. Our results suggest that classical treatment schemes continue to be an effective alternative. More studies should be conducted.
Research perspectives
Classic therapies for HL may still be preferable over novel therapies in middle-income countries. The use of ABVD combined with other immunomodulatory agents could be a potential solution for patients not experiencing favorable outcomes.
